Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM)
Authors:
- Marion DetroitMDMarion Detroit
- Mathis CollierMCMathis Collier
- Nathanaël BeekerNBNathanaël Beeker
- Lise WillemsLWLise Willems
- Justine DecroocqJDJustine Decroocq
- Bénédicte Deau-FischerBDBénédicte Deau-Fischer
- Marguerite VignonMVMarguerite Vignon
- Rudy BirsenRBRudy Birsen
- Frederique MoufleFMFrederique Moufle
- Clément LeclaireCLClément Leclaire
- Elisabeth BalladurEBElisabeth Balladur
- Paul DeschampsPDPaul Deschamps
Open Access
Abstract
Immunotherapy (IT) is a major therapeutic strategy for lymphoma, significantly improving patient prognosis. IT remains ineffective for a significant number of patients, however, and exposes them to specific toxicities. The identification predictive factors around efficacy and toxicity would allow better targeting of patients with a higher ratio of benefit to risk. PRONOSTIM is a multicenter and retrospective study using the Clinical Data Warehouse (CDW) of the Greater Paris University Hospitals network. Adult patients with Hodgkin lymphoma or diffuse large-cell B lymphoma treated with immune checkpoint inhibitors or CAR T (Chimeric antigen receptor T) cells between 2017 and 2022 were included. Analysis of covariates influencing progression-free survival (PFS) or the occurrence of grade ≥3 toxicity was performed. In total, 249 patients were included. From this study, already known predictors for response or toxicity of CAR T cells such as age, elevated lactate dehydrogenase, and elevated C-Reactive Protein at the time of infusion were confirmed. In addition, male gender, low hemoglobin, and hypo- or hyperkalemia were demonstrated to be potential predictive factors for progression after CAR T cell therapy. These findings prove the attractiveness of CDW in generating real-world data, and show its essential contribution to identifying new predictors for decision support before starting IT.Keywords
This publication has 56 references indexed in Scilit:
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysisThe Lancet Oncology, 2018
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialJournal of Clinical Oncology, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)European Journal of Cancer, 2017
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaJournal of Clinical Oncology, 2017
- Sex differences in immune responsesNature Reviews Immunology, 2016
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeJournal of Clinical Oncology, 2016
- Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysisCancer Treatment Reviews, 2016
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998